Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 6/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | PREP | P48147 | 1/20 | 0.44 |
| ▸ | FAP | Q12884 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12634745 | 1.00 | ALDH1A1 (0.52) | ALDH1A1KDM4EMEN1HPGDKMT2A | |
| SCHEMBL12302263 | 1.00 | ALDH1A1 (0.52) | ALDH1A1KDM4EMEN1HPGDKMT2A | |
| SCHEMBL20248643 | 0.95 | ALDH1A1 (0.57) | ALDH1A1KDM4EMEN1HPGDKMT2A | |
| SCHEMBL8546917 | 0.91 | RAB9A (0.50) | ALDH1A1KDM4EMEN1HPGDKMT2A | |
| SCHEMBL12634763 | 0.88 | CTSK (0.52) | ALDH1A1KDM4EMEN1HPGDKMT2A | |
| SCHEMBL12634718 | 0.88 | CTSK (0.52) | ALDH1A1KDM4EMEN1HPGDKMT2A | |
| SCHEMBL16307617 | 0.88 | POLB (0.53) | ALDH1A1KDM4EMEN1HPGDKMT2A | |
| SCHEMBL16307618 | 0.85 | CTSK (0.53) | ALDH1A1KDM4EMEN1HPGDKMT2A | |
| SCHEMBL12137390 | 0.85 | ALDH1A1 (0.48) | ALDH1A1KDM4EMEN1HPGDKMT2A | |
| SCHEMBL18352761 | 0.84 | LTA4H (0.55) | ALDH1A1KDM4EMEN1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606543-B2 | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto | MINDSET PHARMA INC. (CA) | 2026-04-21 | — | — | US | disclosed |
| US-20250250256-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2025-08-07 | — | — | US | disclosed |
| WO-2023201423-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-10-26 | — | — | WO | disclosed |
| EP-4100403-A1 | 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | Mindset Pharma Inc. (CA) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021155467-A1 | 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250256-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TPH1, TPH2, HTR5A | ALDH1A1 1619/4885KDM4E 4240/4885MEN1 2490/4885 |
| US-12606543-B2 | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto | HTR6, CNR1, HTR3C | ALDH1A1 1626/4885KDM4E 4090/4885MEN1 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.